NO996206L - Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer - Google Patents

Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer

Info

Publication number
NO996206L
NO996206L NO996206A NO996206A NO996206L NO 996206 L NO996206 L NO 996206L NO 996206 A NO996206 A NO 996206A NO 996206 A NO996206 A NO 996206A NO 996206 L NO996206 L NO 996206L
Authority
NO
Norway
Prior art keywords
inhibitors
cancer
treatment
combination
coa reductase
Prior art date
Application number
NO996206A
Other languages
English (en)
Norwegian (no)
Other versions
NO996206D0 (no
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO996206D0 publication Critical patent/NO996206D0/no
Publication of NO996206L publication Critical patent/NO996206L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO996206A 1997-06-16 1999-12-15 Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer NO996206L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (2)

Publication Number Publication Date
NO996206D0 NO996206D0 (no) 1999-12-15
NO996206L true NO996206L (no) 2000-02-15

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996206A NO996206L (no) 1997-06-16 1999-12-15 Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (de)
JP (1) JP3713051B2 (de)
KR (1) KR100392573B1 (de)
CN (1) CN1259868A (de)
AP (1) AP9801261A0 (de)
AR (1) AR013090A1 (de)
AT (1) ATE235905T1 (de)
BG (1) BG103946A (de)
BR (1) BR9810616A (de)
CA (1) CA2294399C (de)
CO (1) CO4950607A1 (de)
DE (1) DE69812933T2 (de)
DK (1) DK0986387T3 (de)
DZ (1) DZ2518A1 (de)
EA (1) EA199901043A1 (de)
ES (1) ES2196559T3 (de)
GT (1) GT199800081A (de)
HN (1) HN1998000091A (de)
HR (1) HRP980328B1 (de)
HU (1) HUP0004624A3 (de)
ID (1) ID23014A (de)
IL (1) IL132765A0 (de)
IS (1) IS5259A (de)
MA (1) MA24569A1 (de)
NO (1) NO996206L (de)
NZ (1) NZ500662A (de)
OA (1) OA11231A (de)
PA (1) PA8453601A1 (de)
PE (1) PE82899A1 (de)
PL (1) PL337651A1 (de)
PT (1) PT986387E (de)
SK (1) SK169699A3 (de)
TN (1) TNSN98088A1 (de)
TR (1) TR199903074T2 (de)
UA (1) UA57081C2 (de)
WO (1) WO1998057633A1 (de)
ZA (1) ZA985182B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077949A2 (de) 1998-05-12 2001-02-28 Warner-Lambert Company Kombinationen von hemmern der protein-farnesyl-transferase und der hmg-coa-reduktase und ihre verwendung zur behandlung von krebs
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (de) 1998-12-02 2000-06-07 Pfizer Products Inc. 2-(2-oxo-ethyliden)-imidazolidin-4-one-Derivate und ihre Verwendung zur Inhibierung des abnormalen Zellwachstums
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU7445998A (en) 1999-01-04
AU724676B2 (en) 2000-09-28
CO4950607A1 (es) 2000-09-01
JP3713051B2 (ja) 2005-11-02
PL337651A1 (en) 2000-08-28
KR20010013839A (ko) 2001-02-26
DE69812933D1 (de) 2003-05-08
ZA985182B (en) 1999-12-17
EP0986387A1 (de) 2000-03-22
HUP0004624A2 (hu) 2001-10-28
PA8453601A1 (es) 2000-05-24
HRP980328A2 (en) 1999-04-30
HRP980328B1 (en) 2002-06-30
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
DZ2518A1 (fr) 2003-02-01
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
PT986387E (pt) 2003-06-30
DK0986387T3 (da) 2003-07-14
IL132765A0 (en) 2001-03-19
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
TNSN98088A1 (fr) 2005-03-15
ATE235905T1 (de) 2003-04-15
SK169699A3 (en) 2000-06-12
DE69812933T2 (de) 2003-11-06
WO1998057633A1 (en) 1998-12-23
IS5259A (is) 1999-11-19
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
NZ500662A (en) 2001-10-26
AR013090A1 (es) 2000-12-13
BG103946A (bg) 2000-07-31
EP0986387B1 (de) 2003-04-02
GT199800081A (es) 1999-12-07
TR199903074T2 (xx) 2000-05-22
ID23014A (id) 1999-12-30
ES2196559T3 (es) 2003-12-16
KR100392573B1 (ko) 2003-07-23
OA11231A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
HK1040490A1 (zh) 通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法
NO985652D0 (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
BR9508886A (pt) Compostos e métodos para o tratamento de câncer
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
DE69831222D1 (de) Verbindungen zur immundiagnose von prostatakrebs und deren verwendung
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
NO996206D0 (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
NO20020358L (no) Anvendelse av etodolac til behandling av kreft
HK1038355A1 (en) Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer.
AU6062900A (en) Substituted indole compounds and their use for the treatment of cancer
AU5680900A (en) Combination of mtp inhibitors and hmg-coa reductase inhibitors and the use thereof in medicaments
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
NO20010569D0 (no) Proteaseinhibitorer for anvendelse ved behandling av psoriasis
MXPA02004021A (es) Mezcla terapeutica de inhibidores de hmg-coa reductasa.
SI0986387T1 (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
HUP0201597A2 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
PT1064014E (pt) Medicamento para o impedimento ou tratamento de tumores especificos de papilomavirus
EP1135141A4 (de) Phospholipase inhibitoren zur behandlung von krebs
PL337343A1 (en) Method of obtaining drugs comprising inhibitors of hmg coa reductase
AU2002303182A1 (en) Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the inhibition for the treatment of cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application